{"denoms":[{"counts":[{"groupId":"BG000","value":"253"},{"groupId":"BG001","value":"506"},{"groupId":"BG002","value":"759"}],"units":"Participants"}],"groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"BG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"BG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.15","value":"52.0"},{"groupId":"BG001","spread":"8.61","value":"52.4"},{"groupId":"BG002","spread":"8.79","value":"52.3"}]}]}],"description":"Baseline characteristics were collected for the Intent-to-Treat (ITT) Population, which included all randomized participants in the Double-blind (DB) Phase of the study.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"185"},{"groupId":"BG002","value":"278"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"321"},{"groupId":"BG002","value":"481"}],"title":"Male"}]}],"description":"Baseline characteristics were collected for the Intent-to-Treat (ITT) Population, which included all randomized participants in the Double-blind (DB) Phase of the study.","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"}]}],"title":"African American (A)/African"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"188"},{"groupId":"BG001","value":"388"},{"groupId":"BG002","value":"576"}]}],"title":"White (W)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"59"}]}],"title":"Central/South Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"109"}]}],"title":"Japanese/East Asian /South East Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"American Indian or Alaska Native and White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"African A/African and A Indian/Alaska Native and W"}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study.","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"480"}]}],"title":"Genotype 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"68"}]}],"title":"Genotype 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"160"}]}],"title":"Genotype 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"47"}]}],"title":"Genotype 4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Genotype 5"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Genotype 6"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Genotype 7"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"title":"Missing"}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study. The HCV is a small, enveloped, single-stranded, positive-sense ribonucleic acid (RNA) virus. There are seven major genotypes of HCV, which are indicated numerically from Genotype 1 to 7.","paramType":"NUMBER","title":"Number of participants categorized into the indicated genotype for Hepatitic C Virus (HCV)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"242"},{"groupId":"BG001","value":"487"},{"groupId":"BG002","value":"729"}]}],"title":"Class A"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"28"}]}],"title":"Class B"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Class C"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Missing"}],"description":"The CP score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5-6 = Class A (mild), 7-9 = Class B (moderate), and \\>=10 = Class C (severe).","paramType":"NUMBER","title":"Number of participants categorized into the indicated Child-Pugh (CP) Class","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"347"},{"groupId":"BG002","value":"529"}]}],"title":"Naïve"},{"categories":[{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"230"}]}],"title":"Experienced"}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study. Participants at Baseline were classified as not having used IFN previously (Naïve) or having used IFN previously (Experienced).","paramType":"NUMBER","title":"Number of participants with or without previous interferon (IFN) use","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"65"}]}],"title":"Score: F0/F1/F2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"405"},{"groupId":"BG002","value":"604"}]}],"title":"Score: F3/F4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"90"}]}],"title":"Missing"}],"description":"FibroSURE is a noninvasive blood test that combines the quantitative results of 6 serum biochemical markers (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, γ-glutamyl transpeptidase \\[GGT\\], and ALT) with a participant's age and gender to generate a measure of liver fibrosis/cirrhosis and necroinflammatory activity. It provides a numerical quantitative estimate of liver fibrosis ranging from 0.00 to 1.00, corresponding to the Metavir scoring system of stages F0 to F4 (F0, no fibrosis \\[F\\]; F1, portal F; F2, bridging F with few septa; F3, bridging F with many septa; F4=cirrhosis).","paramType":"NUMBER","title":"Number of participants with the indicated FibroTest/Acti Test (FibroSURE) score","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"162"}]}],"title":"Normal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"204"},{"groupId":"BG001","value":"393"},{"groupId":"BG002","value":"597"}]}],"title":"Elevated"}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study. The normal range of ALT is 0 to 48 International Units per Liter (IU/L).","paramType":"NUMBER","title":"Number of participants with normal or elevated Baseline values for Alanine Aminotransferase (ALT)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2564763.45","value":"1656788.0"},{"groupId":"BG001","spread":"3066411.11","value":"1702729.6"},{"groupId":"BG002","spread":"2907191.97","value":"1687415.8"}]}]}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study. HCV RNA was assessed at baseline of the DB Phase. Data are missing for three participants in the Eltrombopag+Antiviral Therapy treatment group.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Baseline HCV Ribonucleic Acid (RNA)","unitOfMeasure":"International Units per milliliter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.571","value":"56.56"},{"groupId":"BG001","spread":"13.311","value":"56.85"},{"groupId":"BG002","spread":"13.390","value":"56.75"}]}]}],"description":"Baseline characteristics were collected for the ITT Population, which included all randomized participants in the DB Phase of the study. Platelet count eligibility was confirmed at the Baseline visit, prior to administration of eltrombopag, and was defined as the average of the screening and baseline counts, which must be \\<75 Gi/L.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Baseline Platelet Count","unitOfMeasure":"Giga (10^9) cells per liter (Gi/L)"}]}